Nidec aims to achieve two trillion yen in sales, 15% or more in operating income ratio, and 18% or more in return on equity (ROE) by FY2020 based on organic growth and M&A as set out in its new med-term strategic target announced in April 2015.
This page contains a message from the CEO of Nidec, a summary of our performance by product and group, business performance highlights, and IR information such as our disclosure policy and business risk information.
This page contains information for individual investors, including strengths that have enabled Nidec to produce products that occupy leading shares in the market, and efforts to reach the world's No.1 position in various fields.
This page contains the latest information and provides earnings briefings, financial statements, IR presentation materials, and newsletters to stockholders.
This page contains Nidec’s stock and bond information.
This page contains IR schedules and information on the general shareholders’ meeting.
This page introduces you to sites where you can check our company's detailed stock quotations.